Preface W.S. FRED WONG1. Genomic and non-genomic effects of glucocorticoids in respiratory diseasesZhao-Yong Lee and Thai Tran2. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatmentGarry M. Walsh3. Phosphodiesterase inhibitors and lung diseasesIvana Stolfa and Clive Page4. Prospects for macrolide therapy of asthma and COPDMichael J. Parnham, Virginia Norris, Jennifer A. Kricker, Thorarinn Gudjonsson, and Clive P. Page5. Targeting the renin angiotensin system for respiratory diseasesPhyllis X.L. Gan, W. Liao, Kira M. Linke, D. Meid, X.D. Wu, and W.S. Fred Wong6. Progress in the development of kinase inhibitors for treating asthma and COPDNathaniel McClean, Jeffery D. Hasday, and Paul Shapiro7. Anti-fibrotic strategies and pulmonary fibrosisAvanka Gunatilaka, Stephanie Zhang, Wan Shun Daniel Tan, and Alastair G. Stewart8. Novel treatments against airway inflammation in COPD based on drug repurposingRui Chen, Yuting Cui, and Judith C.W. Mak9. Senotherapy for lung diseasesPeter J. Barnes 10. Delivery technology of inhaled therapy for asthma and COPDMichael Y.T. Chow, Harry W. Pan, and Jenny K.W. Lam